NASDAQ · PLTR
Palantir Technologies Inc.
$184.83-$11.59 (-5.9%)
Palantir Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.2% below the high.
Loading market information…
ASX · CC5.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 02:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Clever Culture Systems Limited’s quoted price sits in the lower half of its reported 52-week range, 44.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Clever Culture Systems Limited’s next earnings report is currently expected on Feb 25, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Clever Culture Systems Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, serving markets in Australia, the United States, Sweden, the United Kingdom, China, the Netherlands, and Germany. Its core offering is the Automated Plate Assessment System (APAS), which efficiently images, analyzes, and interprets microbiology culture plates, primarily assisting microbiology laboratories and the pharmaceutical manufacturing sector. The company's portfolio also includes Digital Microbiology and specialized APAS modules—artificial intelligence algorithms designed to enable digital reading of culture plates when integrated with the APAS Independence system. Additionally, Clever Culture Systems is advancing its APAS intelligent imaging technology for diverse applications, including urine screening, infection control testing, and assessing antimicrobial susceptibility. Formerly known as LBT Innovations Limited, the company adopted its current name in November 2024.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$184.83-$11.59 (-5.9%)
Palantir Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.2% below the high.
$190.54-$13.56 (-6.64%)
Atlassian Corporation’s quoted price sits in the upper half of its reported 52-week range, 17.14% below the high.
$23.43-$2.82 (-10.75%)
IREN Limited’s quoted price sits in the lower half of its reported 52-week range, 69.52% below the high.
A$0.21-A$0.01 (-2.33%)
Dimerix Limited’s quoted price sits in the lower half of its reported 52-week range, 68.42% below the high.
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
A$0.08-A$0.01 (-5.62%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 69.45% below the high.
A$0.12+A$0.01 (+9.52%)
Argenica Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.10$0.00 (0.0%)
Chimeric Therapeutics Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
